

CITATION REPORT

List of articles citing

Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate

DOI: 10.1074/jbc.m302267200

Journal of Biological Chemistry, 2003, 278, 41003-12.

Source: <https://exaly.com/paper-pdf/35906448/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
377	Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer. <i>Journal of Virology</i> , 2004 , 78, 12838-47	6.6	18
376	18. THE MOLECULAR VIROLOGY OF HEPATITIS C VIRUS. 2004 , 455-495		
375	Molecular virology of hepatitis C virus. 2004 , 67-85		10
374	C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. <i>Journal of Biological Chemistry</i> , 2004 , 279, 32035-45	5.4	147
373	Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein. 2004 , 173, 446-55		17
372	Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. <i>Journal of Virology</i> , 2004 , 78, 9030-40	6.6	63
371	Strategies for drug discovery by targeting sulfation pathways. 2004 , 9, 967-75		39
370	Heparin-induced cancer cell death. 2004 , 11, 420-2		32
369	Role of glycosaminoglycans in cellular communication. 2004 , 37, 431-8		227
368	Genetic variations in humans associated with differences in the course of hepatitis C. 2004 , 317, 335-41		46
367	Pathophysiology of hepatitis C virus infection and related liver disease. 2004 , 12, 96-102		160
366	Poly(ethylene glycol)-based biosensor chip to study heparin-protein interactions. 2005 , 343, 176-8		27
365	Identification of glycosaminoglycan-binding sites within hepatitis C virus envelope glycoprotein E2*. 2005 , 12, 584-93		16
364	HCV infection of the transplanted liver: changing CD81 and HVR1 variants immediately after liver transplantation. 2005 , 5, 2504-13		9
363	Survey of the year 2003 commercial optical biosensor literature. 2005 , 18, 1-39		90
362	Heparin Regulation of the Complement System. 2005 , 313-343		1
361	Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. <i>Journal of Virology</i> , 2005 , 79, 11095-104	6.6	234

360	Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. <i>Journal of Virology</i> , 2005 , 79, 5774-85	6.6	69
359	Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. <i>Journal of Virology</i> , 2005 , 79, 12692-702	6.6	145
358	Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry. <i>Journal of Virology</i> , 2005 , 79, 15331-41	6.6	69
357	Glycoconjugate glycans as viral receptors. 2005 , 37, 154-72		138
356	Structural characterization of human liver heparan sulfate. 2005 , 1721, 1-8		57
355	Attachment factors. <i>Advances in Experimental Medicine and Biology</i> , 2013 , 790, 1-23	3.6	23
354	Peptide antimicrobial agents. 2006 , 19, 491-511		1759
353	Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. <i>Journal of Virology</i> , 2006 , 80, 10579-90	6.6	150
352	Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. <i>Journal of Virology</i> , 2006 , 80, 8695-704	6.6	204
351	Hepatitis C virus entry: potential receptors and their biological functions. <i>Journal of General Virology</i> , 2006 , 87, 1075-1084	4.9	150
350	Dromedary glycosaminoglycans: molecular characterization of camel lung and liver heparan sulfate. 2006 , 143, 37-43		10
349	Hepatitis C virus E2 links soluble human CD81 and SR-B1 protein. 2006 , 121, 58-64		22
348	A novel virus culture system for hepatitis C virus. 2006 , 1, 519-525		1
347	Virus-Cell Interactions. 2006 ,		
346	How does hepatitis C virus enter cells?. 2006 , 273, 3871-85		23
345	Cell entry of hepatitis C virus. <i>Virology</i> , 2006 , 348, 1-12	3.6	121
344	Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. <i>Virology</i> , 2006 , 352, 357-67	3.6	47
343	Host cell responses induced by hepatitis C virus binding. 2006 , 43, 1326-36		19

342	Hepatitis C virus entry: molecular biology and clinical implications. 2006 , 44, 527-35		102
341	Up-regulation of ERK and p38 MAPK signaling pathways by hepatitis C virus E2 envelope protein in human T lymphoma cell line. 2006 , 80, 424-32		33
340	Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. <i>Journal of Virology</i> , 2006 , 80, 5308-20	6.6	343
339	Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. <i>Journal of General Virology</i> , 2006 , 87, 2583-2593	4.9	68
338	Hepatitis C virus entry depends on clathrin-mediated endocytosis. <i>Journal of Virology</i> , 2006 , 80, 6964-7266		436
337	Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. <i>Journal of Virology</i> , 2006 , 80, 6993-7008	6.6	30
336	The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus. <i>Journal of Biological Chemistry</i> , 2007 , 282, 32357-69	5.4	71
335	Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. <i>Journal of Virology</i> , 2007 , 81, 3933-41	6.6	58
334	Recent advances in our understanding of receptor binding, viral fusion and cell entry of hepatitis C virus: new targets for the design of antiviral agents. 2007 , 18, 169-89		9
333	High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. <i>Journal of Virology</i> , 2007 , 81, 8063-71	6.6	128
332	Mosquito heparan sulfate and its potential role in malaria infection and transmission. <i>Journal of Biological Chemistry</i> , 2007 , 282, 25376-84	5.4	60
331	Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. <i>Journal of Virology</i> , 2007 , 81, 374-83	6.6	218
330	Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. <i>Journal of Virology</i> , 2007 , 81, 8601-12	6.6	63
329	Studying hepatitis C virus: making the best of a bad virus. <i>Journal of Virology</i> , 2007 , 81, 8853-67	6.6	113
328	CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. <i>Journal of Virology</i> , 2007 , 81, 5036-45	6.6	108
327	The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. <i>Journal of Virology</i> , 2007 , 81, 588-98	6.6	185
326	Characterization of herpes simplex virus type 1 recombinants that express and incorporate high levels of HCV E2-gC chimeric proteins. 2007 , 123, 40-9		2
325	Selection of a phage-displayed peptide recognized by monoclonal antibody directed blocking the site of hepatitis C virus E2 for human CD81. 2007 , 68, 601-4		11

324	Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. 2007 , 104, 6025-30		407
323	Hepatitis C virus proteins. <i>World Journal of Gastroenterology</i> , 2007 , 13, 2406-15	5.6	113
322	Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. 2007 , 46, 1722-31		209
321	The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. 2007 , 79, 714-23		56
320	Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection. 2007 , 9, 2445-56		68
319	Hepatitis C virus infection: in vivo and in vitro models. 2007 , 14 Suppl 1, 64-7		18
318	Adenovirus-mediated hepatic syndecan-1 overexpression induces hepatocyte proliferation and hyperlipidaemia in mice. 2007 , 27, 569-81		11
317	Recent contributions of in vitro models to our understanding of hepatitis C virus life cycle. 2007 , 274, 4705-18		4
316	Expression of human liver HSPGs on acute myeloid leukemia. 2007 , 122, 194-206		5
315	Emerging host cell targets for hepatitis C therapy. 2007 , 12, 209-17		23
314	Host range and receptor utilization of canine distemper virus analyzed by recombinant viruses: Involvement of heparin-like molecule in CDV infection. <i>Virology</i> , 2007 , 359, 324-35	3.6	30
313	Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. <i>Virology</i> , 2007 , 366, 40-50	3.6	58
312	The hepatitis C virus life cycle as a target for new antiviral therapies. 2007 , 132, 1979-98		254
311	Virus-host interactions during hepatitis C virus entry – implications for pathogenesis and novel treatment approaches. 2008 , 23, 124-131		1
310	The Importance of Heparan Sulfate in Herpesvirus Infection. 2008 , 23, 383-393		44
309	Binding of liver derived, low density hepatitis C virus to human hepatoma cells. 2008 , 80, 816-23		7
308	Host neutralizing responses and pathogenesis of hepatitis C virus infection. 2008 , 48, 299-307		42
307	Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. 2008 , 48, 1761-8		182

306	Putative hepatitis C virus cell receptors. 2008 , 2, 258-266		0
305	Early steps of the hepatitis C virus life cycle. 2008 , 10, 821-7		95
304	[Neutralizing antibodies in hepatitis C virus infection]. 2008 , 32, 491-8		1
303	Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. 2008 , 317, 1-38		21
302	Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. <i>Journal of Virology</i> , 2008 , 82, 3466-79	6.6	71
301	Physiological, Pathophysiological and Therapeutic Roles of Heparin and Heparan Sulfate. 2008 , 227-251		1
300	Mouse models for the study of HCV infection and virus-host interactions. 2008 , 49, 134-42		47
299	Scavenger receptor BI boosts hepatocyte permissiveness to Plasmodium infection. 2008 , 4, 283-92		94
298	Hepatitis C virus entry. <i>Journal of Biological Chemistry</i> , 2008 , 283, 3689-93	5.4	73
297	Virological characterization of the hepatitis C virus JFH-1 strain in lymphocytic cell lines. <i>Journal of General Virology</i> , 2008 , 89, 1587-1592	4.9	15
296	Tetrasulfated disaccharide unit in heparan sulfate: enzymatic formation and tissue distribution. <i>Journal of Biological Chemistry</i> , 2008 , 283, 31237-45	5.4	35
295	Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. <i>Journal of Virology</i> , 2008 , 82, 12020-9	6.6	137
294	CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. <i>Journal of Virology</i> , 2008 , 82, 5007-20	6.6	154
293	Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. <i>Journal of Virology</i> , 2008 , 82, 569-74	6.6	121
292	Frequent compartmentalization of hepatitis C virus with leukocyte-related amino acids in the setting of liver transplantation. 2008 , 198, 1656-66		18
291	The Impact of Rapid Evolution of Hepatitis Viruses. 2008 , 303-349		7
290	Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. 2009 , 14, 3274-85		34
289	Hepatitis C Virus. 2009 , 1215-1240		

288	Development of hepatitis C virus vaccines: challenges and progress. 2009 , 8, 333-45		70
287	Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts. <i>Journal of Virology</i> , 2009 , 83, 5477-84	6.6	59
286	Novel interactions of glycosaminoglycans and bacterial glycolipids mediate binding of enterococci to human cells. <i>Journal of Biological Chemistry</i> , 2009 , 284, 18194-201	5.4	41
285	Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. <i>Journal of Biological Chemistry</i> , 2009 , 284, 17657-67	5.4	74
284	Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection. <i>Journal of Virology</i> , 2009 , 83, 12714-24	6.6	147
283	Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. <i>Journal of General Virology</i> , 2009 , 90, 1055-1070	4.9	162
282	A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles. <i>Virology</i> , 2009 , 395, 67-76	3.6	48
281	Allelic frequencies of HPA-1 to 5 human platelet antigens in patients infected with hepatitis C virus. 2009 , 81, 757-9		14
280	Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry. 2009 , 16, 89		36
279	Heparan sulfate separation, sequencing, and isomeric differentiation: ion mobility spectrometry reveals specific iduronic and glucuronic acid-containing hexasaccharides. 2009 , 81, 10179-85		46
278	Prospects of RNAi and microRNA-based therapies for hepatitis C. 2009 , 9, 713-24		16
277	Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. 2009 , 137, 673-81		72
276	Gumming up the works: DNA polymers as HCV entry inhibitors. 2009 , 137, 427-30		3
275	Hepatitis C Virus entry: the early steps in the viral replication cycle. 2009 , 6, 117		26
274	Hepatitis C virus virology and new treatment targets. 2009 , 7, 329-50		9
273	The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership. 2009 , 423, 303-14		35
272	Cellular and molecular biology of HCV infection and hepatitis. 2009 , 117, 49-65		98
271	The Involvement of Tight Junction Protein Claudin-1 in Hepatitis C Virus Entry. 2010 , 65, 273-292		1

270	Tight junctions and viral entry. 2010 , 5, 263-271		3
269	Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor. 2010 , 15, 765-73		4
268	Virus de transmissi3 sexual: relaci3 semen y virus. 2010 , 34, 845-853		8
267	Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications. 2010 , 12, e5		78
266	Strategies for antiviral screening targeting early steps of virus infection. 2010 , 25, 281-93		7
265	Role of lipid metabolism in hepatitis C virus assembly and entry. 2009 , 102, 63-74		84
264	The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. <i>Virology</i> , 2010 , 407, 110-9	3.6	14
263	Heparin sulphate D-glucosaminyl 3-O-sulfotransferase 3B1 plays a role in HBV replication. <i>Virology</i> , 2010 , 406, 280-5	3.6	15
262	An assessment of the use of chimpanzees in hepatitis C research past, present and future: 2. Alternative replacement methods. 2010 , 38, 471-94		6
261	Quantitative and qualitative alterations of heparan sulfate in fibrogenic liver diseases and hepatocellular cancer. 2010 , 58, 429-41		56
260	Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. <i>Journal of Virology</i> , 2010 , 84, 10159-68	6.6	163
259	Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. <i>Journal of Virology</i> , 2010 , 84, 5494-507	6.6	56
258	Species-specific regions of occludin required by hepatitis C virus for cell entry. <i>Journal of Virology</i> , 2010 , 84, 11696-708	6.6	45
257	Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display. 2010 , 54, 3355-64		7
256	Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. 2010 , 4, 63-79		7
255	Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. <i>Journal of Virology</i> , 2010 , 84, 964-75	6.6	46
254	Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. <i>Journal of Virology</i> , 2010 , 84, 34-43	6.6	121
253	A novel small molecule inhibitor of hepatitis C virus entry. <i>PLoS Pathogens</i> , 2010 , 6, e1001086	7.6	72

252	Recent advances in hepatitis C virus cell entry. <i>Viruses</i> , 2010 , 2, 692-709	6.2	21
251	Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. <i>PLoS Pathogens</i> , 2010 , 6, e1001142	7.6	61
250	Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. <i>PLoS Pathogens</i> , 2010 , 6, e1000978	7.6	86
249	Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. 2010 , 9, 8		74
248	Virus of Sexual transmission: Semen and virus relationship. 2010 , 34, 845-853		1
247	Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. 2010 , 139, 953-64, 964.e1-4		132
246	Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. 2010 , 16, 277-86		56
245	[Tropism of hepatitis C virus for leukocytes-- importance of the analysis of viral E1 and E2 envelope glycoprotein genes by sequencing]. 2010 , 58, 170-4		
244	The cell biology of receptor-mediated virus entry. 2011 , 195, 1071-82		305
243	Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. <i>Journal of Biological Chemistry</i> , 2011 , 286, 30361-30376	5.4	75
242	Lipoprotein component associated with hepatitis C virus is essential for virus infectivity. 2011 , 1, 19-26		25
241	Unique heparan sulfate from shrimp heads exhibits a strong inhibitory effect on infections by dengue virus and Japanese encephalitis virus. 2011 , 412, 136-42		11
240	A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients. 2011 , 54, 629-39		13
239	Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. 2011 , 54, 566-76		143
238	Japanese encephalitis virus interacts with vimentin to facilitate its entry into porcine kidney cell line. 2011 , 160, 404-8		54
237	Cholesterol and chronic hepatitis C virus infection. 2011 , 41, 697-710		14
236	Virus entry paradigms. 2011 , 41, 1147-57		41
235	Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. 2011 , 54, 1149-56		54

234	Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2. 2011 , 6, 279-94		14
233	The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity. <i>Journal of General Virology</i> , 2011 , 92, 112-21	4.9	40
232	Syndecan-1 and syndecan-2 play key roles in herpes simplex virus type-1 infection. <i>Journal of General Virology</i> , 2011 , 92, 733-43	4.9	57
231	Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry. <i>Journal of Biological Chemistry</i> , 2011 , 286, 31984-92	5.4	36
230	The hepatitis C virus glycan shield and evasion of the humoral immune response. <i>Viruses</i> , 2011 , 3, 1909-32	3.2	74
229	Neutralizing antibodies and pathogenesis of hepatitis C virus infection. <i>Viruses</i> , 2012 , 4, 2016-30	6.2	21
228	Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII). <i>Viruses</i> , 2012 , 4, 2924-44	6.2	12
227	Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides. <i>Bioscience Reports</i> , 2012 , 32, 71-81	4.1	87
226	Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. <i>Journal of Biological Chemistry</i> , 2012 , 287, 35631-35645	5.4	41
225	Blocking HCV entry as potential antiviral therapy. 2012 , 7, 547-561		7
224	A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. 2012 , 205, 1654-64		66
223	Virology of hepatitis C virus infection. 2012 , 26, 381-9		8
222	Development of novel entry inhibitors targeting emerging viruses. 2012 , 10, 1129-38		36
221	Direct-acting and host-targeting HCV inhibitors: current and future directions. 2012 , 2, 588-98		29
220	Hepatitis C virus host cell entry. 2012 , 2, 14-9		71
219	Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. 2012 , 55, 2481-531		219
218	In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against Enterovirus 71. 2012 , 169, 22-9		36
217	Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. <i>Journal of Virology</i> , 2012 , 86, 7256-67	6.6	128

216	Generation of a recombinant reporter hepatitis C virus useful for the analyses of virus entry, intra-cellular replication and virion production. 2012 , 14, 69-78		4
215	Expression of CD81, SR-BI and LDLR in lymphocytes and monocytes from patients with classic and occult hepatitis C virus infection. 2012 , 84, 1727-36		14
214	Liver X receptors agonists impede hepatitis C virus infection in an Idol-dependent manner. 2012 , 95, 245-56		21
213	New targets for treatment against HCV infection. 2012 , 26, 505-15		1
212	Hepatitis C virus entry: role of host and viral factors. 2012 , 12, 1699-709		18
211	Reverse Genetic Tools to Study Hepatitis C Virus. 2012 , 64-90		
210	Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?. <i>Viruses</i> , 2012 , 4, 1731-52	6.2	22
209	Nonviral gene delivery vectors use syndecan-dependent transport mechanisms in filopodia to reach the cell surface. 2012 , 6, 7521-32		49
208	Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins. <i>PLoS ONE</i> , 2012 , 7, e52651	3.7	16
207	Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. <i>Frontiers in Microbiology</i> , 2012 , 3, 54	5.7	26
206	Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropism infection by hepatitis C virus. 2012 , 29, 211-20		14
205	Computational identification of interplay between phosphorylation and O-glycosylation of human occludin as potential mechanism to impair hepatitis C virus entry. 2012 , 12, 1235-45		11
204	Hepatitis E virus enters liver cells through receptor-dependent clathrin-mediated endocytosis. 2012 , 19, 436-48		39
203	Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. 2012 , 19, 449-64		141
202	Fetal bovine serum inhibits hepatitis C virus attachment to host cells. 2013 , 193, 261-9		6
201	Completion of the entire hepatitis C virus life cycle in genetically humanized mice. 2013 , 501, 237-41		184
200	Identification of transferrin receptor 1 as a hepatitis C virus entry factor. 2013 , 110, 10777-82		156
199	Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization. 2013 , 207, 1306-15		8

198	Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. 2013 , 13, 187		116
197	Hepatitis C virus: standard-of-care treatment. 2013 , 67, 169-215		41
196	Glycosaminoglycans in infectious disease. 2013 , 88, 928-43		110
195	Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. 2013 , 19, 837-49		425
194	Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. <i>Journal of Virology</i> , 2013 , 87, 611-20	6.6	135
193	Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. 2013 , 58, 375-84		75
192	Structure and Molecular Virology. 2013 , 219-245		
191	[The molecular biology of hepatitis C virus]. 2013 , 36, 280-93		5
190	Hepatitis C virus vaccines in the era of new direct-acting antivirals. 2013 , 7, 171-85		9
189	Animal models for hepatitis C. 2013 , 369, 49-86		63
188	Hepatitis C virus entry. 2013 , 369, 87-112		109
187	Virus entry at a glance. <i>Journal of Cell Science</i> , 2013 , 126, 1289-95	5.3	148
186	Virus-neutralizing antibodies to hepatitis C virus. 2013 , 20, 369-76		46
185	The Role of CD81 in HCV and Plasmodium Infection. 2013 , 345-386		
184	Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines. <i>Virology</i> , 2013 , 444, 1-113.6		45
183	Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. <i>Viruses</i> , 2013 , 5, 1292-324	6.2	99
182	Hepatocyte polarity. 2013 , 3, 243-87		183
181	Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA. 2013 , 10, 4590-4602		34

180	Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection. 2013 , 22, 853-62		1
179	Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. <i>PLoS Pathogens</i> , 2013 , 9, e1003244	7.6	59
178	Filoviruses utilize glycosaminoglycans for their attachment to target cells. <i>Journal of Virology</i> , 2013 , 87, 3295-304	6.6	54
177	Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. <i>Journal of Virology</i> , 2013 , 87, 6866-75	6.6	94
176	Monoclonal antibodies against Hepatitis C genotype 3a virus like particle inhibit virus entry in cell culture system. <i>PLoS ONE</i> , 2013 , 8, e53619	3.7	8
175	Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry. <i>Journal of Virology</i> , 2013 , 87, 4214-24	6.6	25
174	Hepatitis C virus: virology and life cycle. 2013 , 19, 17-25		98
173	Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. <i>PLoS ONE</i> , 2013 , 8, e76482	3.7	28
172	Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E. <i>PLoS ONE</i> , 2014 , 9, e95550	3.7	51
171	Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy. <i>World Journal of Gastroenterology</i> , 2014 , 20, 15992-6013	5.6	27
170	Recent advances in HCV entry. 2014 , 9, 189-205		2
169	The role of epithelial tight junctions involved in pathogen infections. 2014 , 41, 6591-610		42
168	Glycan Engagement by Viruses: Receptor Switches and Specificity. 2014 , 1, 285-306		70
167	Current and future targets of antiviral therapy in the hepatitis C virus life cycle. 2014 , 9, 947-965		3
166	CD81 and hepatitis C virus (HCV) infection. <i>Viruses</i> , 2014 , 6, 535-72	6.2	61
165	Whole genome sequencing to identify host genetic risk factors for severe outcomes of hepatitis a virus infection. 2014 , 86, 1661-8		5
164	Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. <i>Journal of Virology</i> , 2014 , 88, 1433-46	6.6	78
163	Murine models of hepatitis C: what can we look forward to?. 2014 , 104, 15-22		26

162	Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread. <i>Journal of Virology</i> , 2014 , 88, 5050-61	6.6	27
161	Entry of hepatitis B and C viruses - recent progress and future impact. 2014 , 4, 58-65		40
160	Therapeutic vaccines against hepatitis C virus. 2014 , 22, 120-9		17
159	Macromolecular (pro)drugs in antiviral research. 2014 , 5, 6407-6425		26
158	Virology and cell biology of the hepatitis C virus life cycle: an update. 2014 , 61, S3-S13		116
157	Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins. <i>Journal of Virology</i> , 2014 , 88, 12644-55	6.6	35
156	Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus. 2014 , 109, 141-8		15
155	In vitro Studies and Clinical Trials about Monoclonal Antibodies Used in Infectiology. 2014 , 1195-1214		
154	Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. <i>Journal of Virology</i> , 2014 , 88, 14278-88	6.6	53
153	Entry inhibitors and future treatment of hepatitis C. 2014 , 104, 136-42		17
152	Visualizing hepatitis C virus infection in humanized mice. 2014 , 410, 50-9		13
151	Hepatitis C virus life cycle and lipid metabolism. 2014 , 3, 892-921		73
150	Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds. 2015 , e53124		21
149	Anti-hepatitis C virus strategy targeting host entry factor claudin-1. 2015 , 65, 245-254		
148	Claudin-1 gene variants and susceptibility to hepatitis C infection in HIV-1 infected intravenous drug users (an ANRS case-control study). 2015 , 87, 619-24		3
147	Substantial Receptor-induced Structural Rearrangement of Rotavirus VP8*: Potential Implications for Cross-Species Infection. 2015 , 16, 2176-81		6
146	Apolipoprotein E and protection against hepatitis E viral infection in American non-Hispanic blacks. 2015 , 62, 1346-52		22
145	Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. <i>Viruses</i> , 2015 , 7, 3995-4046	6.2	38

144	Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. <i>Viruses</i> , 2015 , 7, 5659-85	6.2	44
143	Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro. <i>PLoS ONE</i> , 2015 , 10, e0142539	3.7	7
142	Identification of Variants of Hepatitis C Virus (HCV) Entry Factors in Patients Highly Exposed to HCV but Remaining Uninfected: An ANRS Case-Control Study. <i>PLoS ONE</i> , 2015 , 10, e0142698	3.7	4
141	Porcine epidemic diarrhea virus uses cell-surface heparan sulfate as an attachment factor. 2015 , 160, 1621-8		30
140	Gene Therapy for Hepatitis C Virus Infection. 2015 , 191-226		
139	Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans. <i>Journal of Virology</i> , 2015 , 89, 3846-58	6.6	50
138	Susceptibility to <i>Plasmodium yoelii</i> preerythrocytic infection in BALB/c substrains is determined at the point of hepatocyte invasion. 2015 , 83, 39-47		17
137	Rapid Uptake and Inhibition of Viral Propagation by Extracellular OAS1. 2015 , 35, 359-66		7
136	The mechanism of HCV entry into host cells. 2015 , 129, 63-107		75
135	Gene therapies for hepatitis C virus. <i>Advances in Experimental Medicine and Biology</i> , 2015 , 848, 1-29	3.6	5
134	Advanced molecular surveillance of hepatitis C virus. <i>Viruses</i> , 2015 , 7, 1153-88	6.2	9
133	Interaction of human tumor viruses with host cell surface receptors and cell entry. <i>Viruses</i> , 2015 , 7, 2592-6617		37
132	Host cell kinases and the hepatitis C virus life cycle. 2015 , 1854, 1657-62		16
131	Heparanase is a host enzyme required for herpes simplex virus-1 release from cells. 2015 , 6, 6985		88
130	Targeting Viral Entry for Treatment of Hepatitis B and C Virus Infections. 2015 , 1, 420-7		28
129	Claudins and pathogenesis of viral infection. 2015 , 42, 39-46		7
128	The missing pieces of the HCV entry puzzle. 2015 , 10, 415-428		6
127	Generation of improved mouse models for the study of hepatitis C virus. 2015 , 759, 313-25		11

126	Advances in experimental systems to study hepatitis C virus in vitro and in vivo. <i>Virology</i> , 2015 , 479-480, 221-33	3.6	30
125	Discovery of Imidazo[1,2- <i>b</i>]naphthyridine Derivatives as Potential HCV Entry Inhibitor. 2015 , 6, 977-81		15
124	Functional and Biochemical Characterization of Hepatitis C Virus (HCV) Particles Produced in a Humanized Liver Mouse Model. <i>Journal of Biological Chemistry</i> , 2015 , 290, 23173-87	5.4	24
123	The role of cellular adhesion molecules in virus attachment and entry. 2015 , 370, 20140035		43
122	Bridging the past and the future of virology: surface plasmon resonance as a powerful tool to investigate virus/host interactions. 2015 , 41, 238-60		17
121	Hepatitis C Virus. 2016 , 1313-1345		
120	Glycosaminoglycans and infection. 2016 , 21, 1260-77		85
119	Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes. <i>PLoS ONE</i> , 2016 , 11, e0154498	3.7	19
118	Interaction between hepatic membrane type 1 matrix metalloproteinase and acireductone dioxygenase 1 regulates hepatitis C virus infection. 2016 , 23, 256-66		7
117	Japanese encephalitis virus invasion of cell: allies and alleys. 2016 , 26, 129-41		27
116	Evolution of the Humoral Response during HCV Infection: Theories on the Origin of Broadly Neutralizing Antibodies and Implications for Vaccine Design. 2016 , 129, 55-107		7
115	A Schisandra-Derived Compound Schizandronic Acid Inhibits Entry of Pan-HCV Genotypes into Human Hepatocytes. <i>Scientific Reports</i> , 2016 , 6, 27268	4.9	12
114	Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals. 2016 , 10, 741-8		24
113	Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection. 2016 , 224, 46-57		4
112	A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I. <i>Journal of Virology</i> , 2016 , 90, 10499-10512	6.6	10
111	An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions. <i>Journal of Virology</i> , 2016 , 90, 8720-8	6.6	13
110	Dendrimeric based microbicides against sexual transmitted infections associated to heparan sulfate. 2016 , 6, 46755-46764		11
109	Potent in vitro antiviral activity of <i>Cistus incanus</i> extract against HIV and Filoviruses targets viral envelope proteins. <i>Scientific Reports</i> , 2016 , 6, 20394	4.9	40

108	Lipid and Lipoprotein Components Play Important Roles the Egress and Infectivity of Hepatitis C Virions. 2016 , 255-272		0
107	HCV Receptors and Virus Entry. 2016 , 81-103		2
106	SULF1/SULF2 reactivation during liver damage and tumour growth. 2016 , 146, 85-97		7
105	A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. 2016 , 63, 35-48		102
104	Entry inhibitors: New advances in HCV treatment. 2016 , 5, e3		47
103	HCV infection, IFN response and the coding and non-coding host cell genome. 2016 , 212, 85-102		14
102	Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors and. 2017 , 61,		5
101	Hepatitis C virus may have an entero-hepatic cycle which could be blocked with ezetimibe. 2017 , 102, 51-55		1
100	Cyanobacterial lectins characteristics and their role as antiviral agents. 2017 , 102, 475-496		31
99	Claudins in viral infection: from entry to spread. 2017 , 469, 27-34		12
98	Heparan Sulfate Proteoglycan Is an Important Attachment Factor for Cell Entry of Akabane and Schmallenberg Viruses. <i>Journal of Virology</i> , 2017 , 91,	6.6	18
97	Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo. <i>Journal of Virology</i> , 2017 , 91,	6.6	15
96	The potential of signal peptide peptidase as a therapeutic target for hepatitis C. 2017 , 21, 827-836		2
95	Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. 2017 , 8, 503		59
94	Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7. 2017 , 152, 257-270.e7		26
93	Regulated Entry of Hepatitis C Virus into Hepatocytes. <i>Viruses</i> , 2017 , 9,	6.2	30
92	Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro. 2017 , 2017, 4828936		15
91	Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies. <i>Journal of General Virology</i> , 2017 , 98, 962-976	4.9	5

90	Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model. <i>Journal of Virology</i> , 2018 , 92,	6.6	17
89	Single Particle Imaging of Polarized Hepatoma Organoids upon Hepatitis C Virus Infection Reveals an Ordered and Sequential Entry Process. 2018 , 23, 382-394.e5		49
88	The Multifaceted Roles of Autophagy in Flavivirus-Host Interactions. 2018 , 19,		30
87	Disruption of Claudin-1 Expression by miRNA-182 Alters the Susceptibility to Viral Infectivity in HCV Cell Models. 2018 , 9, 93		2
86	Animal Models to Study Hepatitis C Virus Infection. <i>Frontiers in Immunology</i> , 2018 , 9, 1032	8.4	23
85	Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design. <i>Frontiers in Immunology</i> , 2018 , 9, 1436	8.4	29
84	Plasmodium sporozoites can invade hepatocytic cells independently of the Ephrin receptor A2. <i>PLoS ONE</i> , 2018 , 13, e0200032	3.7	16
83	Transcriptomics Sequencing Provides Insights into Understanding the Mechanism of Grass Carp Reovirus Infection. 2018 , 19,		13
82	Downstream Products are Potent Inhibitors of the Heparan Sulfate 2-O-Sulfotransferase. <i>Scientific Reports</i> , 2018 , 8, 11832	4.9	8
81	The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses. 2018 , 75, 3895-3905		11
80	The role of tacstd-2 level in hepatitis C patients (controlled clinical research). 2019 , 14, 1622363		
79	Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study. <i>Scientific Reports</i> , 2019 , 9, 13593	4.9	6
78	A hepatitis B virus-derived human hepatic cell-specific heparin-binding peptide: identification and application to a drug delivery system. 2018 , 7, 322-335		8
77	Role of heparan sulfate in entry and exit of Ross River virus glycoprotein-pseudotyped retroviral vectors. <i>Virology</i> , 2019 , 529, 177-185	3.6	5
76	Building a mechanistic mathematical model of hepatitis C virus entry. <i>PLoS Computational Biology</i> , 2019 , 15, e1006905	5	12
75	Immunopathogenesis of Liver Injury During Hepatitis C Virus Infection. <i>Viral Immunology</i> , 2019 , 32, 112-120		11
74	The polymeric immunoglobulin receptor-like protein from Marsupinaeus japonicus is a receptor for white spot syndrome virus infection. <i>PLoS Pathogens</i> , 2019 , 15, e1007558	7.6	27
73	Evolution of efficacious pangenotypic hepatitis C virus therapies. <i>Medicinal Research Reviews</i> , 2019 , 39, 1091-1136	14.4	10

72	Hepatitis C Virus Entry: Protein Interactions and Fusion Determinants Governing Productive Hepatocyte Invasion. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020 , 10,	5.4	23
71	Evaluating Heparin Products for Heparin-Induced Thrombocytopenia Using Surface Plasmon Resonance. <i>Journal of Pharmaceutical Sciences</i> , 2020 , 109, 975-980	3.9	5
70	Equid Herpesvirus-1 Exploits the Extracellular Matrix of Mononuclear Cells to Ensure Transport to Target Cells. <i>IScience</i> , 2020 , 23, 101615	6.1	3
69	Envelope proteins as antiviral drug target. <i>Journal of Drug Targeting</i> , 2020 , 28, 1046-1052	5.4	6
68	Immunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment. <i>Frontiers in Immunology</i> , 2020 , 11, 574276	8.4	28
67	Hepatitis B and C Viruses. 2020 ,		1
66	Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 589505	5.9	43
65	On the Host Side of the Hepatitis E Virus Life Cycle. <i>Cells</i> , 2020 , 9,	7.9	4
64	A Genome-Wide CRISPR-Cas9 Screen Reveals the Requirement of Host Cell Sulfation for Schmallenberg Virus Infection. <i>Journal of Virology</i> , 2020 , 94,	6.6	12
63	T-cell immunoglobulin and mucin (TIM) contributes to the infection of human airway epithelial cells by pseudotype viruses containing Hantaan virus glycoproteins. <i>Virology</i> , 2020 , 543, 54-62	3.6	8
62	Evasion of a Human Cytomegalovirus Entry Inhibitor with Potent Cysteine Reactivity Is Concomitant with the Utilization of a Heparan Sulfate Proteoglycan-Independent Route of Entry. <i>Journal of Virology</i> , 2020 , 94,	6.6	3
61	Syndecan 4 Upregulation on Activated Langerhans Cells Counteracts Langerin Restriction to Facilitate Hepatitis C Virus Transmission. <i>Frontiers in Immunology</i> , 2020 , 11, 503	8.4	3
60	Dispirotriperazine-core compounds, their biological activity with a focus on broad antiviral property, and perspectives in drug design (mini-review). <i>European Journal of Medicinal Chemistry</i> , 2021 , 211, 113014	6.8	4
59	Novel combined single dose anti-hepatitis C therapy: a pilot study. <i>Scientific Reports</i> , 2021 , 11, 4623	4.9	1
58	Cellular metabolism in the defense against microbes. <i>Journal of Cell Science</i> , 2021 , 134,	5.3	3
57	Glycosaminoglycan-Protein Interactions and Their Roles in Human Disease. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 639666	5.6	25
56	Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. <i>Vaccines</i> , 2021 , 9,	5.3	2
55	Emerging Roles of Heparan Sulfate Proteoglycans in Viral Pathogenesis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 283-294	5.3	5

54	Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies. <i>Pathogens</i> , 2021 , 10,	4.5	4
53	Heparanase as a potential player in SARS-CoV-2 infection and induced coagulopathy. <i>Bioscience Reports</i> , 2021 , 41,	4.1	2
52	From Cancer to COVID-19: A Perspective on Targeting Heparan Sulfate-Protein Interactions. <i>Chemical Record</i> , 2021 , 21, 3087-3101	6.6	8
51	Cellular factors involved in the hepatitis C virus life cycle. <i>World Journal of Gastroenterology</i> , 2021 , 27, 4555-4581	5.6	1
50	Antiviral strategies should focus on stimulating the biosynthesis of heparan sulfates, not their inhibition. <i>Life Sciences</i> , 2021 , 277, 119508	6.8	0
49	The degree of polymerization and sulfation patterns in heparan sulfate are critical determinants of cytomegalovirus entry into host cells. <i>PLoS Pathogens</i> , 2021 , 17, e1009803	7.6	2
48	Two New Purification Methods of Hepatitis C Virus Particles from Serum-Free Culture System. <i>Hepatitis Monthly</i> , 2021 , 21,	1.8	0
47	Protease, Growth Factor, and Heparanase-Mediated Syndecan-1 Shedding Leads to Enhanced HSV-1 Egress. <i>Viruses</i> , 2021 , 13,	6.2	2
46	Expression of Syndecan-1 in Chronic Liver Diseases: Correlation With Hepatic Fibrosis. <i>In Vivo</i> , 2021 , 35, 333-339	2.3	2
45	Interaction between respiratory syncytial virus and glycosaminoglycans, including heparan sulfate. <i>Methods in Molecular Biology</i> , 2007 , 379, 15-34	1.4	32
44	Heparanase, Heparan Sulfate and Viral Infection. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1221, 759-770	3.6	19
43	Extrahepatic Replication of HCV. 2016 , 165-184		1
42	Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein. <i>Journal of General Virology</i> , 2011 , 92, 494-506	4.9	31
41	Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. <i>Journal of General Virology</i> , 2005 , 86, 677-685	4.9	46
40	The Degree of Polymerization and Sulfation Patterns in Heparan Sulfate are Critical Determinants of Cytomegalovirus Entry into Host Cells.		1
39	T-cell immunoglobulin and mucin (TIM) contributes to Hantaan virus entry into human airway epithelial cells.		1
38	A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. <i>PLoS ONE</i> , 2011 , 6, e23699	3.7	21
37	Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures. <i>PLoS ONE</i> , 2013 , 8, e65273	3.7	6

36	Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors. <i>PLoS ONE</i> , 2013 , 8, e67982	3.7	43
35	Interactions between Hepatitis C Virus and the Human Apolipoprotein H Acute Phase Protein: A Tool for a Sensitive Detection of the Virus. <i>PLoS ONE</i> , 2015 , 10, e0140900	3.7	6
34	Members of 3-O-Sulfotransferases (3-OST) Family: A Valuable Tool from Zebrafish to Humans for Understanding Herpes Simplex Virus Entry. <i>The Open Virology Journal</i> , 2013 , 7, 5-11	1.9	9
33	Neutralizing antibodies in hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2007 , 13, 4824-306	3.6	36
32	Heparanase and hepatocellular carcinoma: promoter or inhibitor?. <i>World Journal of Gastroenterology</i> , 2010 , 16, 306-11	5.6	12
31	How hepatitis C virus invades hepatocytes: the mystery of viral entry. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3457-67	5.6	38
30	Autophagy in hepatitis C virus-host interactions: potential roles and therapeutic targets for liver-associated diseases. <i>World Journal of Gastroenterology</i> , 2014 , 20, 5773-93	5.6	27
29	Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. <i>World Journal of Gastroenterology</i> , 2014 , 20, 15975-91	5.6	14
28	Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy. <i>World Journal of Gastroenterology</i> , 2015 , 21, 8492-507	5.6	20
27	Chronic hepatitis C virus infection and lipoprotein metabolism. <i>World Journal of Gastroenterology</i> , 2015 , 21, 10299-313	5.6	35
26	Host restriction factors for hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2016 , 22, 1477-86	5.6	13
25	Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2. <i>World Journal of Hepatology</i> , 2017 , 9, 368-384	3.4	5
24	LDL receptor and pathogen processes: Functions beyond normal lipids. <i>Journal of Clinical Lipidology</i> , 2021 ,	4.9	
23	Proposition d'une nouvelle stratégie pour éviter la réinfection du greffon par le virus de l'hépatite C après transplantation hépatique. <i>Bulletin De L'Académie Nationale De Médecine</i> , 2008 , 192, 1657-1668	0.1	
22	Hepatitis C. 2010 , 1313-1335.e6		1
21	Hepatitis C. 582-652		
20	Role of Glycans in Viral Infection. 2015 , 71-93		
19	Development of an infectious surrogate hepatitis C virus based on a recombinant vesicular stomatitis virus expressing hepatitis C virus envelope glycoproteins and green fluorescent protein. <i>Japanese Journal of Infectious Diseases</i> , 2015 , 68, 203-8	2.7	

18	Molecular Mechanisms of Hepatitis C Virus Entry Impact of Host Cell Factors for Initiation of Viral Infection. 2015 , 189-202		
17	B Cell Responses and Control of HCV Infection. 2016 , 331-357		
16	Molecular Events of Hepatitis C in Hepatocellular Carcinoma. <i>Gastroenterology & Hepatology (Bartlesville, Okla)</i> , 2016 , 4,	0.2	
15	Building a mechanistic mathematical model of hepatitis C virus entry.		
14	The knowledge on HCV. <i>Infectious Microbes & Diseases</i> , 2022 , Publish Ahead of Print,	1.3	○
13	Structural Characterization of Ectodomain G Protein of Respiratory Syncytial Virus and Its Interaction with Heparan Sulfate: Multi-Spectroscopic and In Silico Studies Elucidating Host-Pathogen Interactions. <i>Molecules</i> , 2021 , 26,	4.8	○
12	A Comprehensive View on the Host Factors and Viral Proteins Associated With Porcine Epidemic Diarrhea Virus Infection.. <i>Frontiers in Microbiology</i> , 2021 , 12, 762358	5.7	○
11	DataSheet1.DOC. 2018 ,		
10	Image1.PNG. 2018 ,		
9	Image_1.jpg. 2020 ,		
8	Image_2.jpg. 2020 ,		
7	Image_3.jpg. 2020 ,		
6	Image_4.jpg. 2020 ,		
5	Image_5.jpg. 2020 ,		
4	Harnessing Human Papillomavirus Natural Tropism to Target Tumors. 2022 , 14, 1656		○
3	Efficient production of inhibitor-free foamy virus glycoprotein-containing retroviral vectors by proteoglycan-deficient packaging cells. 2022 , 26, 394-412		
2	The Alterations and Roles of Glycosaminoglycans in Human Diseases. 2022 , 14, 5014		○
1	Specialized metabolites from plants as a source of new multi-target antiviral drugs: a systematic review.		○

